Despite the profitability miss, FY 23/24 guidance unchanged
09/02/24 -"CZM’s Q1 profitability fell short of expectations. Growth was once again led by Microsurgery, while Ophthalmology ended on a flat note. As expected, profitability was under pressure. Nonetheless, FY ..."
Pages
66
Language
English
Published on
09/02/24
You may also be interested by these reports :
14/10/25
Since our last Carl Zeiss Meditec (CZM; BUY; Germany) idea kicker in June 2024, a lot has gone wrong for the German Medtech. Results weakened due to: ...
10/10/25
Key conclusions: Chinese manufacturers can produce Meta Rayban-like glasses for €25. The margin dilution impact of Meta Ray-Ban is probably lower ...
10/10/25
We have removed the long term margin dilution from Meta Ray-Ban in our model as we think the dilution won’t be as significant as we had previously ...
08/10/25
Sartorius is scheduled to report its Q3 2025 earnings on the 16th of October. Interestingly, the stock has surged c. 14% from 30 September to 7 ...